Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
REDWOOD CITY, Calif., May 30, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:
- 14th Annual Craig-Hallum Institutional 1x1 Investor Conference on Wednesday, May 31st at The Depot Renaissance Minneapolis Hotel in Minneapolis.
- Jefferies 2017 Global Healthcare Conference on Thursday, June 8, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference will be held in New York City.
A live webcast and replay of the presentation at the Jefferies Global Healthcare Conference will be available on the Investors section of the company’s website, http://ir.codexis.com/.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts: Investors LHA Jody Cain, 310 691 7100 [email protected]
